公开(公告)号：US20140228320A1

公开(公告)日：2014-08-14

申请号：US14253139

申请日：2014-04-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiko TANIGUCHI ,  Masato YOSHIKAWA ,  Kasei MIURA ,  Tomoaki HASUI ,  Eiji HONDA ,  Keisuke IMAMURA ,  Makoto KAMATA ,  Haruhi KAMISAKI ,  John F. QUINN ,  Joseph RAKER ,  Fatoumata CAMARA ,  Yi WANG

IPC: C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D498/04 ,  C07F7/10

CPC classification number: A61K31/4353 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/551 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04 ,  C07D471/14 ,  C07D473/00 ,  C07D473/28 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07D498/08 ,  C07D519/00 ,  C07F7/10

Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia or so on represented by the formula (I):

Abstract translation: 本发明提供具有PDE抑制作用的化合物，其可用作预防或治疗由式（I）表示的精神分裂症等的药剂：

公开(公告)号：US20170197983A1

公开(公告)日：2017-07-13

申请号：US15467548

申请日：2017-03-23

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki KOIKE ,  Yuichi KAJITA ,  Masato YOSHIKAWA ,  Shuhei IKEDA ,  Eiji KIMURA ,  Tomoaki HASUI ,  Toshiya NISHI ,  Hiromi FUKUDA

IPC: C07D498/08 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D471/10 ,  C07D405/14 ,  C07D213/74 ,  C07D239/42 ,  C07D401/04 ,  C07D401/14 ,  C07D487/18

CPC classification number: C07D498/08 ,  A61K9/2018 ,  A61K9/4858 ,  C07D213/12 ,  C07D213/72 ,  C07D213/74 ,  C07D239/42 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D451/02 ,  C07D451/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/08 ,  C07D487/10 ,  C07D487/18 ,  C07D491/08 ,  C07D491/18 ,  C12N9/99

Abstract: An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20230357220A1

公开(公告)日：2023-11-09

申请号：US17999514

申请日：2021-05-20

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tomoaki HASUI ,  Satoshi MIKAMI, JR. ,  Toru YAMASHITA ,  Shinji NAKAMURA ,  Shinji MORIMOTO ,  Toshihiro IMAEDA ,  Kazuaki TAKAMI ,  Masaki DAINI ,  Hiroyuki KAKEI ,  Minoru NAKAMURA ,  Fumie YAMAGUCHI ,  Chunxiang WANG ,  Sachie TAKASHIMA ,  Makoto KAMATA ,  Yuya OGURO ,  Shuhei IKEDA

IPC: C07D413/14 ,  C07D405/14 ,  C07D401/14

CPC classification number: C07D413/14 ,  C07D401/14 ,  C07D405/14

Abstract: Abstract: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer’s disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

公开(公告)号：US20160052897A1

公开(公告)日：2016-02-25

申请号：US14781665

申请日：2014-04-03

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki KOIKE ,  Masato YOSHIKAWA ,  Izumi NOMURA ,  Yoshiteru ITO ,  Eiji KIMURA ,  Haruhi ANDO ,  Tomoaki HASUI ,  Toshiya NISHI

IPC: C07D263/32 ,  C07D491/08 ,  C07D413/04 ,  C07D413/14 ,  C07D413/12 ,  C07D413/10

CPC classification number: C07D263/32 ,  C07D413/04 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D491/08

Abstract: The present invention relates to a compound represented by the formula (I), which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. In the formula (I), each symbol is as defined in the specification.

Abstract translation: 本发明涉及式（I）表示的化合物，其可用作预防或治疗癫痫，神经变性疾病等的药剂。 在式（I）中，每个符号如说明书中所定义。

公开(公告)号：US20230348435A1

公开(公告)日：2023-11-02

申请号：US17999505

申请日：2021-05-20

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tomoaki HASUI ,  Satoshi MIKAMI ,  Toru YAMASHITA ,  Shinji NAKAMURA ,  Shinji MORIMOTO ,  Toshihiro IMAEDA ,  Kazuaki TAKAMI ,  Masaki DAINI ,  Hiroyuki KAKEI ,  Minoru NAKAMURA ,  Fumie YAMAGUCHI ,  Chunxiang WANG ,  Sachie TAKASHIMA ,  Shogo HASHIZUME

IPC: C07D403/06 ,  A61K45/06 ,  C07D413/14 ,  C07D403/14 ,  C07D401/14 ,  C07D405/14

CPC classification number: C07D403/06 ,  A61K45/06 ,  C07D413/14 ,  C07D403/14 ,  C07D401/14 ,  C07D405/14

Abstract: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 1-(OH-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 100 to page 143; examples 1 to 167; test examples 1 and 2; tables 1 to 4).

公开(公告)号：US20130303553A1

公开(公告)日：2013-11-14

申请号：US13944370

申请日：2013-07-17

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiko TANIGUCHI ,  Masato YOSHIKAWA ,  Kasei MIURA ,  Tomoaki HASUI ,  Eiji HONDA ,  Keisuke IMAMURA ,  Makoto KAMATA ,  Haruhi KAMISAKI

IPC: C07D471/04 ,  C07D473/00 ,  C07D498/04

CPC classification number: A61K31/4353 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/551 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04 ,  C07D471/14 ,  C07D473/00 ,  C07D473/28 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07D498/08 ,  C07D519/00 ,  C07F7/10

Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia. The compound is represented by the formula (I): wherein the symbols are defined in the specification.

Abstract translation: 本发明提供具有PDE抑制作用的化合物，其可用作预防或治疗精神分裂症的药剂。 化合物由式（I）表示：其中符号在说明书中定义。

公开(公告)号：US20230278999A1

公开(公告)日：2023-09-07

申请号：US17819818

申请日：2022-08-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tomoaki HASUI ,  Shinji NAKAMURA ,  Satoshi MIKAMI ,  Tohru YAMASHITA

IPC: C07D471/04 ,  C07D407/12 ,  C07D413/10 ,  C07D413/14

CPC classification number: C07D471/04 ,  C07D407/12 ,  C07D413/10 ,  C07D413/14

Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer’s disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like.
The present invention relates to a compound represented by the formula (I):





wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20200270243A1

公开(公告)日：2020-08-27

申请号：US16753613

申请日：2018-10-04

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shinji NAKAMURA ,  Satoshi MIKAMI ,  Tomoaki HASUI ,  Tohru YAMASHITA ,  Shinji MORIMOTO ,  Hidekazu TOKUHARA ,  Norio OYABU ,  Masami YAMADA ,  Atsuko OCHIDA ,  Kazuaki TAKAMI ,  Xin LIU

IPC: C07D471/04 ,  C07D519/00 ,  C07D487/04 ,  A61K9/20

Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20150315209A1

公开(公告)日：2015-11-05

申请号：US14650429

申请日：2013-12-10

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki KOIKE ,  Yuichi KAJITA ,  Masato YOSHIKAWA ,  Shuhei IKEDA ,  Eiji KIMURA ,  Tomoaki HASUI ,  Toshiya NISHI ,  Hiromi FUKUDA

IPC: C07D498/08 ,  C07D413/14 ,  C07D417/14 ,  C07D403/04 ,  C07D405/14 ,  C07D471/10 ,  C07D401/04 ,  C07D401/14 ,  C07D471/08

CPC classification number: C07D498/08 ,  A61K9/2018 ,  A61K9/4858 ,  C07D213/12 ,  C07D213/72 ,  C07D213/74 ,  C07D239/42 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D451/02 ,  C07D451/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/08 ,  C07D487/10 ,  C07D487/18 ,  C07D491/08 ,  C07D491/18 ,  C12N9/99

Abstract: An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 本发明的目的是提供具有优异CH24H抑制作用的化合物，其可用作预防或治疗癫痫，神经变性疾病等的药剂。 本发明涉及由下式表示的化合物：其中每个符号如说明书中所定义，或其盐。